Overview
TEVA market data
Business OverviewA provider-written description of this company or fund, with its source and observation date.
Teva Pharmaceutical, based in Israel, is the world's leading generic drug manufacturer. Teva derives half its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in two main therapeutic areas: neurology and immunology. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.
- Source
- massive
- Observed
- Cadence
- Reference data reviewed periodically
- Status
- fresh
Price HistoryDaily closing prices from recorded market data. The latest point represents the most recent completed daily period; prices can move before the next point appears.
TEVA price chart · 1M
- O
- 42.06
- H
- 42.68
- L
- 41.54
- C
- 42.62
- Vol
- 361,739.00
Daily history from Jul 8, 2025
- Source
- US equities market feed
- Observed
- Cadence
- Five-minute page cache; daily and stored hourly bars
- Status
- fresh
Key Stats & PerformanceOpen, range, return and notional-volume facts calculated from daily market bars.
- Open
- $42.06
- Previous Close
- $42.57
- Day High
- $42.68
- Day Low
- $41.54
- 52 Week High
- $44.57
- 52 Week Low
- $24.01
- 7 Day Return
- +0.53%
- 30 Day Return
- +3.22%
- 90 Day Return
- +13.74%
- 1 Year Return
- +73.32%
- Daily Notional Volume
- $15.4M Latest daily bar volume multiplied by its closing price.
Valuation & ProfitabilityProvider-backed valuation, profitability, and range metrics for the selected company. Display-only; never feeds scores or decisions.
- P/E (TTM)
- 99.68 Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- $1.21 Diluted earnings per share over the trailing twelve months.
- Beta
- 0.38 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- 3.0% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $7,732.00 – $14,440.00 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- $41.00 Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $165.1B · P/B 4.49 · P/S 2.94.
Company NewsRecent source-attributed headlines linked to this symbol. Repeated headlines and low-signal items are filtered. Open a headline for its source and context.
10 captured
FDA Clears Teva's Newly Acquired At-Home Agitation Treatment in Schizophrenia and Bipolar DisorderBenzinga ·
FDA Approves Teva's IGALMI for At-Home UseFiscal.ai ·
Global Injectables Market is Anticipated to Surpass USD 1 Trillion Mark by 2034 | DelveInsightGlobenewswire Inc ·
Peptide Therapeutics Market: Global Size, Share, Trends and Forecast to 2036 | Set to Reach $229.32 Billion as GLP-1, Oral Peptides, Radioligands, and Generics Fuel GrowthGlobenewswire Inc ·
Paracetamol Market to Exceed USD 15 Billion by 2032 Driven by Rising Demand for Pain Relief and Fever Management, Reports Mordor IntelligenceGlobenewswire Inc ·